Industry top-down
Biotechnology
Latest reported revenue & EPS across the covered companies in this industry, with year-over-year (YoY) change. From disclosed earnings — not investment advice.
28 companiesMedian revenue YoY: +31.1%EPS beat rate: —
AI industry top-down
바이오테크놀로지 커버리지 기업들의 매출 성장률 중앙값은 29.63%로 외형 확장이 두드러집니다. 다수 기업이 두 자릿수 이상의 매출 성장을 기록했으나, 순이익 측면에서는 일부 기업의 EPS가 역성장하거나 데이터가 부재하는 등 수익성 편차가 존재합니다.
- 매출 성장률 중앙값 29.63% 기록 및 대다수 외형 확대
- 인스메드, 알테오젠 등 일부 기업의 세 자릿수 매출 성장률 달성
- 상당수 기업의 주당순이익(EPS) 및 컨센서스 서프라이즈 데이터 부재
Where companies diverge: 매출 증가세 속 리제네론(-4.53%), 로열티파마(-42.86%) 등 EPS 역성장 발생 · 로이반트 사이언스의 역성장(-33.55%) 대비 여타 기업들의 큰 폭 매출 증가
AI synthesis of disclosed results and analyst research across these companies — not investment advice.
Companies — latest quarter
| Company | Period | Revenue | Rev YoY | EPS | EPS YoY | Surprise |
|---|---|---|---|---|---|---|
| VRTXVERTEX PHARMACEUTICALS INC / MA | FY2026 Q3 | $3.44B | +11.8% | $2.56 | -39.0% | — |
| MRNAModerna, Inc. | FY2026 Q3 | $1.31B | +29.2% | $0.38 | — | — |
| REGNREGENERON PHARMACEUTICALS, INC. | FY2026 Q3 | $5.12B | +36.3% | $18.45 | +35.5% | — |
| 207940SAMSUNG BIOLOGICS CO.,LTD. | FY2025 Q3 | ₩1.66T | +39.9% | ₩8071.00 | +117.2% | — |
| ONCBeOne Medicines Ltd. | FY2026 Q3 | $1.89B | +33.8% | $0.25 | +212.5% | — |
| RVMDRevolution Medicines, Inc. | FY2026 Q3 | $197.56M | — | $-1.90 | — | — |
| RPRXRoyalty Pharma plc | FY2026 Q3 | $690.1M | +13.3% | $0.32 | -52.2% | — |
| 068270Celltrion, Inc. | FY2026 Q2 | ₩1.39T | +45.0% | ₩1609.00 | — | — |
| BEIGFBeOne Medicines Ltd. | FY2026 Q3 | $1.89B | +33.8% | $0.25 | +212.5% | — |
| ROIVRoivant Sciences Ltd. | FY2027 Q2 | $35.12M | — | $-0.27 | — | — |
| INSMINSMED Inc | FY2026 Q3 | $524.43M | +268.4% | $-0.46 | — | — |
| INCYINCYTE CORP | FY2026 Q3 | $1.56B | +14.0% | $-3.86 | — | — |
| ALNYALNYLAM PHARMACEUTICALS, INC. | FY2026 Q3 | $1.46B | +16.7% | $15.72 | — | — |
| EXELEXELIXIS, INC. | FY2027 Q3 | $658.7M | +10.2% | $0.85 | +23.2% | — |
| JAZZJazz Pharmaceuticals plc | FY2026 Q3 | $1.24B | +10.4% | $-7.48 | — | — |
| BBIOBridgeBio Pharma, Inc. | FY2026 Q3 | $353.17M | +192.6% | $-0.42 | — | — |
| SMMTSummit Therapeutics Inc. | FY2024 Q3 | $0 | — | $-0.08 | — | — |
| HALOHALOZYME THERAPEUTICS, INC. | FY2026 Q3 | $492.97M | +39.2% | $2.01 | +40.6% | — |
| KYMRKymera Therapeutics, Inc. | FY2026 Q3 | $0 | -100.0% | $-1.32 | — | — |
| TECHBIO-TECHNE Corp | FY2027 Q1 | $299.71M | +4.6% | $0.18 | -25.0% | — |
| BMRNBIOMARIN PHARMACEUTICAL INC | FY2026 Q3 | $1.02B | +32.0% | $-0.63 | — | — |
| MDGLMADRIGAL PHARMACEUTICALS, INC. | FY2026 Q3 | $431.27M | +50.1% | $1.83 | — | — |
| SYRESpyre Therapeutics, Inc. | FY2024 Q3 | $0 | — | $1.06 | — | — |
| PRAXPraxis Precision Medicines, Inc. | FY2025 Q3 | $0 | -100.0% | $-3.36 | — | — |
| TGTXTG THERAPEUTICS, INC. | FY2026 Q3 | $259.94M | +60.7% | $0.35 | -85.6% | — |
| 196170Alteogen Inc. | FY2026 Q2 | ₩68.89B | +269.5% | ₩531.00 | — | — |
| KRYSKrystal Biotech, Inc. | FY2026 Q3 | $127.34M | +30.2% | $2.05 | -22.9% | — |
| CRNXCrinetics Pharmaceuticals, Inc. | FY2026 Q1 | $361K | -43.6% | $-1.04 | — | — |
YoY = vs. the same quarter last year · Surprise = EPS actual vs. consensus. Latest reported quarter per company, from disclosed earnings filings. QoQ is omitted because quarterly filings don’t break out Q4 (US) and report cumulatively (KR).